Shares of Outset Medical, Inc. (OM) have gained 9.6% over the past four weeks to close the last trading session at $11.01, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $18.90 indicates a potential upside of 71.7%.The mean estimate comprises five short-term price targets with a standard deviation of $14.91. While the lowest estimate of $7.50 indicates a 31.9% decline from the ...

SAN JOSE, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the first quarter 2025 after the close of trading on Wednesday, May 7, 2025. On the same day, at 2:00 p.m. Pacific time (5:00 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Nabeel Ahmed, Chief Financial Officer ...

Outset Medical, Inc. (OM) closed the last trading session at $10.91, gaining 15.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.49 indicates an 188.6% upside potential.The average comprises five short-term price targets ranging from a low of $7.50 to a high of $45, with a standard deviation of $18.67. While the lowest estimate indicates a decline of 31.3% from the current pr ...

SAN JOSE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced a one-for-fifteen reverse stock split (the "Reverse Stock Split") of the Company's common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Thursday, March 20, 2025. The Company's common stock will continue to trade under Outset's ...

(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-0514392 (State or other jurisdiction of ...

A downtrend has been apparent in Outset Medical, Inc. (OM) lately. While the stock has lost 9.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case fo ...

Core Viewpoint - In 2025, Bitcoin has underperformed expectations, struggling to maintain its value above $100,000, with only a 5% increase for the year, prompting investors to seek alternative cryptocurrencies that may outperform Bitcoin [1]. Group 1: Alternative Cryptocurrencies - XRP has increased over 400% since the presidential election and 30% in 2025, benefiting from a pro-crypto regulatory environment under the Trump administration, with potential resolution of regulatory issues from the SEC [3][4]. - XRP is speculated to be a candidate for a new spot ETF approval, with current trading around $2.70 and price predictions reaching as high as $10, depending on investor interest in ETFs [5]. - Bittensor has a market cap of nearly $4 billion and is up 3% for the year, focusing on AI projects and recently listed on Coinbase, which boosted its price by 20% [6][8]. - Bittensor has a limited supply of 21 million coins, similar to Bitcoin, contributing to its high price of $450 due to scarcity [9]. - Mantra has seen a 99% increase year-to-date and an astonishing 43,927% since October 2023, focusing on real-world asset tokenization for financial institutions [10][11]. - The asset tokenization market is projected to be a multitrillion-dollar opportunity by 2030, with significant potential for growth in various asset classes [13][14]. Group 2: Market Context - Despite Bitcoin's strong historical performance, XRP, Bittensor, and Mantra are positioned to potentially deliver substantial gains over the next five years, although they carry higher risks [15].

SAN JOSE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 45th annual TD Cowen Health Care conference on Tuesday, March 4, 2025, at 2:30 p.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors ...

Outset Medical, Inc. (NASDAQ:OM) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Jim Mazzola - Head of Investor Relations Leslie Trigg - Chair and CEO Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Outset Medical Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-on ...

Core Insights - Outset Medical reported fourth-quarter earnings that exceeded analysts' expectations, with revenue of $29.5 million surpassing the forecast of $28 million, indicating resilience in revenue growth despite market challenges [2][3] - The company achieved significant improvements in operational efficiency and gross margins, with adjusted gross margin reaching 37.7%, up from 27.1% year-over-year [4][7] Financial Performance - Adjusted EPS loss was $0.37, better than the projected loss of $0.44, and a significant improvement from the loss of $0.54 in Q4 2023 [4] - Net revenue decreased by 3.3% year-over-year from $30.5 million in Q4 2023 to $29.5 million in Q4 2024 [4] - Adjusted net loss was $19.3 million, an improvement from the $27 million loss in the previous year [4] Business Model and Strategy - Outset Medical is known for its Tablo Hemodialysis System, which simplifies dialysis treatment and reduces costs, with a focus on increasing market penetration in acute and home settings [5][6] - The company is enhancing its sales strategies and customer support to broaden the adoption of the Tablo system [6] Operational Highlights - Gross margin improved significantly due to higher average selling prices for consoles and reduced operational costs [7] - Recurring revenue from consumables and services grew by 17% year-over-year, indicating a shift towards sustainable revenue generation [8] - Operating expenses were reduced by 28% year-over-year, contributing to the pathway to profitability [8] Future Outlook - Management anticipates continued improvements in gross margins, aiming for non-GAAP gross margins in the high-30% range [9] - Revenue projections for 2025 estimate growth between $115 million and $125 million, reflecting confidence in market expansion [9] - The company plans to reduce cash usage to under $50 million, enhancing its financial position for future initiatives [10]